Based on these findings, we hypothesize that tumors with elevated DDR may exhibit increased responses to combined LSD1 inhibitor and immunotherapy combinations currently being evaluated in SCLC (NCT05191797). The gene discussed is KDM1A; the disease is small cell lung carcinoma.